An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
Basic Trial Information
|No phase specified||Natural history/Epidemiology||18 and over||ML28257|
This multi-center, prospective observational study will evaluate the treatment patterns, and
the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible
patients will have an initial metastatic breast cancer diagnosis that has not been
previously treated with systemic therapy; patients may be enrolled up to 6 months after the
diagnosis. Data will be collected for up to 8 years.
Availability of cancer-specific historical data points in the patient's medical
Initial diagnosis of HER2+ MBC, as diagnosed by the treating physician, no more than
6 months prior to study enrollment
Adult patients, >/=18 years of age
Any inability to provide informed consent
Trial Contact Information
Trial Lead Organizations / Sponsors / Collaborators
UCLA / Jonsson Comprehensive Cancer Center
Sara Alsterlind Hurvitz
USC / Norris Comprehensive Cancer Center
Darcy Vernon Spicer
Medical University of South Carolina
Neal Paul Christiansen
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01615068
Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.